Health Canada's leading researchers, including Dr. Tara Barton-Maclaren, Dr. Matthew Gagne, Dr. Matthew Meier, Dr. Kristin Eccles, and Dr. Marc Beal, are spearheading transformative approaches to chemical risk assessment.

Through a multifaceted strategy encompassing non-animal methods, computational models, transcriptome profiling, high-throughput phenotypic profiling, and organ-on-a-chip technologies, they are revolutionizing the field. Their collective efforts emphasize Canada's global leadership in driving innovations forward, leveraging international collaborations, and advancing regulatory decision-making. By decoding cellular gene expression patterns, identifying early biomarkers of harm, and integrating various data sources, they are enhancing the accuracy, efficiency, and ethicality of risk assessment practices. Their pioneering work promises to ensure the safety of Canadians and the environment while reducing reliance on traditional animal testing methods.